Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections
AIM: This study aimed to characterize the first-dose and steady-state pharmacokinetic parameters of colistin in critically-ill patients. BACKGROUND: Increased prevalence of multidrug resistant Gram-negative bacterial infections among critically-ill patients has revived the use of colistin. There is...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524002613 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850051075014393856 |
|---|---|
| author | Harivenkatesh Natarajan Surya Singaravelu Venkateswaran Ramanathan Smitha Kayal Apurba Sankar Sastry Pankaj Kundra |
| author_facet | Harivenkatesh Natarajan Surya Singaravelu Venkateswaran Ramanathan Smitha Kayal Apurba Sankar Sastry Pankaj Kundra |
| author_sort | Harivenkatesh Natarajan |
| collection | DOAJ |
| description | AIM: This study aimed to characterize the first-dose and steady-state pharmacokinetic parameters of colistin in critically-ill patients. BACKGROUND: Increased prevalence of multidrug resistant Gram-negative bacterial infections among critically-ill patients has revived the use of colistin. There is a dire need to characterize the pharmacokinetics of colistin to find out the dosing required to achieve the optimal pharmacokinetic/pharmacodynamic(PK/PD) indices such as Cmax/MIC and AUC/MIC to ensure maximum efficacy and safety. METHODS: In this prospective observational pharmacokinetic study, we studied the first dose and steady state pharmacokinetics of colistin in 16 critically ill patients who received a loading dose of 9 million IU of colistimethate sodium (CMS), followed by maintenance dose of either 4.5 million IU twice daily (n=9) or 3 million IU thrice daily (n=7). Plasma levels of colistin were estimated using LC-MS/MS and pharmacokinetic parameters were estimated using non-compartmental model. RESULTS: We observed a wide inter-individual variability in the pharmacokinetic parameters of colistin. No significant difference was seen in the steady state pharmacokinetic parameters between two different maintenance dosing regimens. Clinical resolution was seen in 8 (50%)patients, nephrotoxicity in 6 (37.5%)patients and bacteriological eradication following repeat culture was seen in 6 (37.5%)patients. PK/PD indices such as AUC/MIC and Cmax/MIC was higher in patients with clinical resolution and bacteriological eradication but this was not statistically significant. CONCLUSION: The lower rates of clinical and microbiological efficacy, and occurrence of adverse events such as nephrotoxicity mandates the need for therapeutic drug monitoring of colistin and individualization of CMS dose for achieving optimal outcome. |
| format | Article |
| id | doaj-art-5d5abe5d71af4a70b442610795b36fea |
| institution | DOAJ |
| issn | 2213-7165 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj-art-5d5abe5d71af4a70b442610795b36fea2025-08-20T02:53:16ZengElsevierJournal of Global Antimicrobial Resistance2213-71652024-12-01392710.1016/j.jgar.2024.10.084Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infectionsHarivenkatesh Natarajan0Surya Singaravelu1Venkateswaran Ramanathan2Smitha Kayal3Apurba Sankar Sastry4Pankaj Kundra5Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, IndiaDepartment of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, IndiaDepartment of Internal Medicine, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, IndiaDepartment of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, IndiaDepartment of Microbiology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, IndiaDepartment of Anesthesiology, Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Puducherry, IndiaAIM: This study aimed to characterize the first-dose and steady-state pharmacokinetic parameters of colistin in critically-ill patients. BACKGROUND: Increased prevalence of multidrug resistant Gram-negative bacterial infections among critically-ill patients has revived the use of colistin. There is a dire need to characterize the pharmacokinetics of colistin to find out the dosing required to achieve the optimal pharmacokinetic/pharmacodynamic(PK/PD) indices such as Cmax/MIC and AUC/MIC to ensure maximum efficacy and safety. METHODS: In this prospective observational pharmacokinetic study, we studied the first dose and steady state pharmacokinetics of colistin in 16 critically ill patients who received a loading dose of 9 million IU of colistimethate sodium (CMS), followed by maintenance dose of either 4.5 million IU twice daily (n=9) or 3 million IU thrice daily (n=7). Plasma levels of colistin were estimated using LC-MS/MS and pharmacokinetic parameters were estimated using non-compartmental model. RESULTS: We observed a wide inter-individual variability in the pharmacokinetic parameters of colistin. No significant difference was seen in the steady state pharmacokinetic parameters between two different maintenance dosing regimens. Clinical resolution was seen in 8 (50%)patients, nephrotoxicity in 6 (37.5%)patients and bacteriological eradication following repeat culture was seen in 6 (37.5%)patients. PK/PD indices such as AUC/MIC and Cmax/MIC was higher in patients with clinical resolution and bacteriological eradication but this was not statistically significant. CONCLUSION: The lower rates of clinical and microbiological efficacy, and occurrence of adverse events such as nephrotoxicity mandates the need for therapeutic drug monitoring of colistin and individualization of CMS dose for achieving optimal outcome.http://www.sciencedirect.com/science/article/pii/S2213716524002613PolymyxinColistinMDR Gram-negative infectionPharmacokineticsPK/PDCritically-ill |
| spellingShingle | Harivenkatesh Natarajan Surya Singaravelu Venkateswaran Ramanathan Smitha Kayal Apurba Sankar Sastry Pankaj Kundra Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections Journal of Global Antimicrobial Resistance Polymyxin Colistin MDR Gram-negative infection Pharmacokinetics PK/PD Critically-ill |
| title | Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections |
| title_full | Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections |
| title_fullStr | Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections |
| title_full_unstemmed | Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections |
| title_short | Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections |
| title_sort | pharmacokinetics of colistin in patients with multi drug resistant gram negative bacterial infections |
| topic | Polymyxin Colistin MDR Gram-negative infection Pharmacokinetics PK/PD Critically-ill |
| url | http://www.sciencedirect.com/science/article/pii/S2213716524002613 |
| work_keys_str_mv | AT harivenkateshnatarajan pharmacokineticsofcolistininpatientswithmultidrugresistantgramnegativebacterialinfections AT suryasingaravelu pharmacokineticsofcolistininpatientswithmultidrugresistantgramnegativebacterialinfections AT venkateswaranramanathan pharmacokineticsofcolistininpatientswithmultidrugresistantgramnegativebacterialinfections AT smithakayal pharmacokineticsofcolistininpatientswithmultidrugresistantgramnegativebacterialinfections AT apurbasankarsastry pharmacokineticsofcolistininpatientswithmultidrugresistantgramnegativebacterialinfections AT pankajkundra pharmacokineticsofcolistininpatientswithmultidrugresistantgramnegativebacterialinfections |